MITOCHONDRIAL-TARGETED PEPTIDE / CLINICAL RESEARCH
SS-31, also known as elamipretide, MTP-131, and Bendavia, is a mitochondria-targeted tetrapeptide investigated for interactions with the inner mitochondrial membrane and mitochondrial function.
PRIMARY RESEARCH AREAS
Mitochondrial biology; cardiolipin interactions; mitochondrial energetics; oxidative phosphorylation; skeletal-muscle function; primary mitochondrial disease; Barth syndrome; aging-related mitochondrial research.
EVIDENCE LEVEL
SS-31/elamipretide has been investigated across cellular models, animal studies, and controlled human clinical trials. Evidence varies substantially by disease, population, and endpoint. Elamipretide received FDA accelerated approval in September 2025 under the brand name Forzinity for improving muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg; this does not establish efficacy for broader uses.
SS-31 and elamipretide refer to the same mitochondria-targeted tetrapeptide, historically also called MTP-131 and Bendavia. Research has examined mitochondrial membrane biology, cardiolipin-associated mechanisms, and disease-specific clinical outcomes.
SS-31, also known as elamipretide, is a mitochondria-targeted tetrapeptide studied for its relationship with the inner mitochondrial membrane, cardiolipin-associated biology, mitochondrial energetics, and oxidative phosphorylation. It progressed from preclinical research into human clinical development. FDA accelerated approval for Forzinity in Barth syndrome is disease-specific and does not establish effectiveness for general mitochondrial enhancement, aging, athletic performance, fatigue, longevity, or other unapproved applications.
Mitochondrial dysfunction is studied across inherited mitochondrial disorders, aging, skeletal-muscle dysfunction, cardiovascular biology, metabolic disease, and other areas. A mitochondria-targeted compound became scientifically interesting because disease-specific mitochondrial abnormalities may involve membrane structure, energetics, and oxidative phosphorylation. Disease-specific clinical findings must remain separate from general mitochondrial hypotheses.
Overlapping research areas provide a rationale for studying the constituents together, but they do not establish additive or synergistic effects.
Evidence for GLOW should be read as separate GHK-Cu, BPC-157, and thymosin beta-4 / TB-500 contexts rather than as evidence for a single tested product. The concise evidence matrix below summarizes the cellular, preclinical, and human landscape.
Important limitations include disease-specific responses, mixed clinical findings across populations, unsuccessful primary endpoints in MMPOWER-3, long-term outcomes, generalizability, and the difference between mechanistic improvements and clinically meaningful outcomes. FDA approval for Barth syndrome does not establish effectiveness for unrelated uses.
Primary-source references should distinguish controlled human trials, mechanistic research, and regulatory materials. MMPOWER-3: PubMed-indexed record PMID 37268435. FDA Forzinity accelerated-approval materials are the authoritative source for the Barth syndrome indication. References and claims are limited to evidence that can be verified for the exact compound, formulation, disease population, or biological system described.
References and claims are limited to evidence that can be verified for the exact compound or formulation.
Evidence involving individual constituents should be interpreted according to the exact compound, formulation, route, population and endpoint studied. Controlled human evidence specifically evaluating the combined 50 mg GHK-Cu / 10 mg BPC-157 / 10 mg TB-500 formulation has not been established.
CELLULAR / IN-VITRO EVIDENCE
Cellular evidence addresses mitochondrial, cardiolipin, membrane, energetic, and related mechanisms. It is mechanistic evidence rather than proof of human clinical benefit.
ANIMAL / PRECLINICAL EVIDENCE
Animal and disease-model research informs mitochondrial, muscle, cardiovascular, aging, and metabolic hypotheses. It should not be presented as human evidence.
Elamipretide has substantial human clinical investigation compared with many research peptides, including randomized trials. The record includes positive disease-specific regulatory conclusions for Barth syndrome and negative primary endpoints in primary mitochondrial myopathy, underscoring population-specific interpretation.
Mitochondrial mechanism and cardiolipin research: primarily mechanistic and preclinical. Primary mitochondrial myopathy: MMPOWER-3 did not meet its primary endpoints. Barth syndrome: FDA accelerated approval in 2025 is a disease-specific regulatory conclusion. Still under investigation: long-term outcomes, broader applications outside Barth syndrome, aging and longevity claims, and translation of mitochondrial mechanisms into meaningful human outcomes.
Safety has been evaluated in controlled human trials in defined populations. Injection-site reactions and other treatment-emergent events should be interpreted from the specific trial record. Safety in studied populations does not establish safety for unstudied populations, formulations, doses, or uses.
Remaining questions include long-term clinical outcomes, disease-specific efficacy, mitochondrial biomarkers versus functional outcomes, durability, population differences, broader applications outside Barth syndrome, aging and longevity claims, and translation of preclinical mitochondrial findings into meaningful human outcomes.
EDITORIALLY REVIEWED
LAST REVIEWED
Research profile reviewed for source accuracy, evidence classification, mitochondrial biology, cardiolipin and membrane mechanisms, preclinical evidence, controlled human evidence, regulatory status, safety evidence, and distinction between demonstrated clinical outcomes and broader proposed applications.